Status:
COMPLETED
The Effect of Zoledronic Acid on Bone Density in Liver Transplant Patients
Lead Sponsor:
Royal Prince Alfred Hospital, Sydney, Australia
Collaborating Sponsors:
Novartis
Conditions:
Osteoporosis
Liver Transplantation
Eligibility:
All Genders
17-70 years
Phase:
PHASE4
Brief Summary
Following liver transplantation, rapid bone loss occurs, particularly within the first 6 months post-transplant. This may be associated with fractures, most notable vertebral. The ability to assess os...
Detailed Description
This study is a prospective, randomised, double-blind, placebo-controlled clinical trial in liver transplant patients comparing therapy with the bisphosphonate, zoledronate, to patients who do not rec...
Eligibility Criteria
Inclusion
- Greater than 17 years of age
Exclusion
- Concurrent treatment, or within the past 12 months, with drugs known to affect bone metabolism
- Hypocalcemia
- Renal impairment (creatinine \>1.5x ULN)
Key Trial Info
Start Date :
February 1 2000
Trial Type :
INTERVENTIONAL
End Date :
August 1 2004
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00114556
Start Date
February 1 2000
End Date
August 1 2004
Last Update
May 9 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Prince Alfred Hospital
Sydney, New South Wales, Australia, 2050